The impact of adjunctive aripiprazole on QT interval: A 12-week open label study in patients on olanzapine, clozapine or risperidone

被引:0
|
作者
Pilunthanakul, Thanita [1 ,5 ]
Ting, Mable Quek Jing [1 ]
Lee, Jimmy [2 ,3 ,4 ]
Gupta, Bhanu [1 ]
机构
[1] Inst Mental Hlth, Dept Emergency & Crisis Care, Singapore, Singapore
[2] Inst Mental Hlth, Dept Psychosis, Singapore, Singapore
[3] Inst Mental Hlth, Res Div, Singapore, Singapore
[4] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore
[5] Inst Mental Hlth, Dept Emergency & Crisis Care, 10 Buangkok View,Buangkok Green,Med Pk, Singapore 539747, Singapore
基金
英国医学研究理事会;
关键词
adjunctive antipsychotic; aripiprazole; atypical antipsychotics; QT prolongation; schizoaffective; schizophrenia; DISRUPTIVE BEHAVIOR DISORDERS; DOUBLE-BLIND; SUBAVERAGE INTELLIGENCE; MAINTENANCE TREATMENT; CHILDREN; SAFETY; PLACEBO; ADOLESCENTS; EFFICACY; SCHIZOPHRENIA;
D O I
10.1002/hup.2863
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To evaluate the effect of adjunct aripiprazole on QT of patients clinically stabilized on atypical antipsychotics.Methods: The dataset was from an open-label 12-week prospective trial that evaluated adjunctive use of 5 mg/day of aripiprazole on metabolic profile in patients with schizophrenia, or schizoaffective disorder stabilized on olanzapine, clozapine, or risperidone. Bazett-corrected QT (QTc) was manually calculated from ECGs measured at baseline (before aripiprazole) and week 12, by two doctors blind to the diagnosis and atypical antipsychotic. The change in QTc ( increment QTc: baseline QTc-week 12 QTc) and the number of participants in normal, borderline, prolonged, and pathological groups after 12 weeks were analyzed.Results: Fifty-five participants, mean age of 39.3 (SD 8.2) years, were analyzed. The increment QTc after 12 weeks was 5.9 ms (p = 0.143) for the whole sample; 16.4 ms (p = 0.762), 3.7 ms (p = 0.480) and 0.5 ms (p = 0.449), for the clozapine, risperidone and olanzapine group, respectively. There was no significant statistical difference comparing the change in QTc overall, and between atypical antipsychotic groups, when evaluating from baseline to endpoint. However, stratifying the sample based on sex-dependent QTc cut-offs showed a 45% decrease in abnormal QTc readings (p = 0.049) after aripiprazole initiation; 20 subjects had abnormal QTc at baseline, while only 11 subjects had abnormal QTc at 12 weeks. 25.5% of participants showed a reduction in at least one QTc severity group, while 65.5% had no change and 9.0% worsened in QTc group, after 12 weeks of adjunct aripiprazole.Conclusion: Low-dose adjunctive aripiprazole did not prolong QTc in patients stabilized on either olanzapine, risperidone, or clozapine. More controlled studies evaluating the QTc effect of adjunctive aripiprazole should be done to confirm and support these findings.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial
    Lublin, Henrik
    Haug, Hans-Joachim
    Koponen, Hannu
    Sigmundsson, Thordur
    Kolb, Stefan A.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (04): : 710 - 718
  • [2] Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: A naturalistic prospective 12-week observational study
    Strous, Rael D.
    Kupchik, Marina
    Roitman, Suzana
    Schwartz, Sima
    Gonen, Noach
    Mester, Roberto
    Weizman, Abraham
    Spivak, Baruch
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2006, 21 (04) : 235 - 243
  • [3] A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients
    Takekita, Yoshiteru
    Kato, Masaki
    Wakeno, Masataka
    Sakai, Shiho
    Suwa, Azusa
    Nishida, Keiichiro
    Okugawa, Gaku
    Kinoshita, Toshihiko
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2013, 40 : 110 - 114
  • [4] Aripiprazole versus olanzapine in a 52-week, open-label extension study
    McQuade, R
    Kostic, D
    Marcus, R
    Carson, W
    Torbeyns, A
    Kerselaers, W
    Yocca, F
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 496 - 497
  • [5] Reboxetine Adjuvant Therapy in Patients With Schizophrenia Showing a Suboptimal Response to Clozapine A 12-Week, Open-Label, Pilot Study
    Bruno, Antonio
    Zoccali, Rocco
    Bellinghieri, Paolo Micali
    Pandolfo, Gianluca
    De Fazio, Pasquale
    Spina, Edoardo
    Muscatello, Maria Rosaria A.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (05) : 620 - 623
  • [6] Effect of metformin on olanzapine-induced weight gain: A 12-week randomised open-label study
    Kumar, G. Chetan
    Sarala, N.
    Reddy, M. Mohan
    Manjunath, H.
    JOURNAL OF CLINICAL SCIENCES, 2025, 22 (01) : 11 - 17
  • [7] Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
    Gabriel, Adel
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 711 - 717
  • [8] Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study
    Pae, Chi-Un
    Jeon, Hong Jin
    Lee, Boung Chul
    Seo, Ho-Jun
    Kim, Shin Gyeom
    Park, E-Jin
    Kim, Won
    Kwak, Kyung-Phil
    Han, Changsu
    Cho, Seong-Jin
    Hahn, Sang-Woo
    Jon, Duk-In
    Choi, Jin-Hyuk
    Jun, Tae-Youn
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (06) : 322 - 329
  • [9] Aripiprazole versus olanzapine in schizophrenia: A 52-week, open-label extension study
    McQuade, R
    Kostic, D
    Marcus, R
    Carson, W
    Iwamoto, T
    Torbeyns, A
    Kerselaers, W
    Yocca, F
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S173 - S174
  • [10] Aripiprazole therapy in 20 older adults with bipolar disorder: A 12-week, open-label trial
    Sajatovic, Martha
    Coconcea, Nicoleta
    Ignacio, Rosalinda V.
    Blow, Frederic C.
    Hays, Robert W.
    Cassidy, Kristin A.
    Meyer, William J.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (01) : 41 - 46